Seed funding

GBP pound sterling funding
#Alentis Therapeutics #Curve Therapeutics #Drug discovery #Finance #Funding #Pfizer Ventures #Seed funding #Solid tumours

£40.5 million invested in discovery platform and to advance pipeline 

Curve Therapeutics, a company developing an intracellular screening platform to address disease targets, has completed a £40.5 million ($51.37 million) Series A financing round. Pfizer Ventures led the round with participation from Columbus Venture Partners and British Patient Capital, which join founding investor Advent Life Sciences and… Read More

#News

Cell and gene therapy
#Cell and gene therapy #MIP Discovery #Seed funding

£7M to drive commercialisation in cell and gene therapies (CGTs) 

MIP Discovery has closed a £7 million GBP (~$9 million USD) Series A financing round, which enables the company to refocus its mission on improving the downstream processing of cell and gene therapies (CGTs), to accelerate widespread adoption of these potentially life-changing medicines.    MIP Discovery develops non-biological… Read More

#News

Peptide
#Cancer research #HBC Immunology #Oncology #Peptides #Prostate cancer #Seed funding #Tumour microenvironment (TME)

Start-up to study peptides that modulate gene expression

HBC Immunology (a subsidiary of Hofseth BioCare) has secured seed capital financing of approximately $900,000 from external investors to commence preclinical animal trials with its patented peptides, FT-002 and FT-005. These are analogues of peptides discovered by HBC in ProGo bioactive peptides, which modulate iron metabolism… Read More

#News #Start-up Zone

Seed funding
#AI / data analytics / healthtech / informatics #Investment #Omics #Seed funding #SMi Systems #Start-ups

SMi discloses £6 million seed funding round

SMi Systems has disclosed a £6m ($7.6m) seed funding round to develop and prove the utility of its multi-omic platform for in vitro diagnosis and biomedical research. SMi hopes the technology will significantly accelerate the discovery of new therapeutics by biopharma companies and research institutions. Read More

#News #Start-up Zone

Double stranded DNA molecule with mutation in a gene
#Cystic fibrosis #Life sciences #Seed funding #Start-ups #Therapeutics

€2m raised in seed funding to develop novel therapies for Cystic Fibrosis  

Anoat Therapeutics, a preclinical stage biotechnology company specialised in Cystic Fibrosis (CF), has raised €2m ($2.17m) in seed funding from AdBio partners, a venture capital company specialised in seed investments in life sciences startups.   This investment from the AFB FII fund stems from the AdBio-Inserm Transfert partnership… Read More

#News #Start-up Zone

#Funding #Investment #Private investment #Seed funding

DDW Highlights Podcast for 30 May 2023 now live

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The theme of DDW’s news review this week is money. Although Clarivate has reported a recent… Read More

#News

#Funding #Investment #Private investment #Seed funding

This week in drug discovery (22-26 May)

News round-up for 22-26 May by DDW Digital Content Editor Diana Spencer. The theme of our news review this week is money. Although Clarivate has reported a recent drop in investment in the industry, it is good to see companies raising money through funding rounds and… Read More

#News

Seed fund
#BioInnovation Institute #Denmark #Immunotherapy #InProTher #Investment #Oncology #Seed funding #Start-ups

Danish immunotherapy start-up raises €6M seed funding

Danish start-up InProTher has raised €6 million seed funding from private investors, with participation from the European Innovation Council (EIC) Fund. The financing will enable InProTher to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumours, into clinical development. Incubated at the BioInnovation Institute (BII) and seeded… Read More

#Business & Investment #News #Start-up Zone

Start-up hopes to boost production of viral vectors for ATMPs
#AAV #Advanced Therapy Medicinal Products (ATMPs) #Cell and gene therapy #Seed funding #Start-ups

Start-up hopes to boost production of viral vectors for ATMPs

New South African company NewBiologix has launched with the aim of developing a proprietary and breakthrough platform for the advanced engineering of cell lines used to manufacture gene and cell therapies. The company’s DNA-based platform is being developed to address manufacturing challenges associated with the production… Read More

#News #Start-up Zone

AI brain
#AI / data analytics / healthtech / informatics #Drug discovery #Funding #MultiOmic Health #Precision medicine #Seed funding #Start-ups

AI platform focuses on precision medicines for metabolic syndromes

AI drug discovery company MultiOmic Health has closed a £5 million ($6.2 million) seed funding extension round to build a precision therapeutics discovery platform for metabolic syndrome-related medical conditions. The round was led by London-based Hoxton Ventures, with participation from Ada Ventures, MMC Ventures and Verve… Read More

#News #Start-up Zone

Adcendo Lab
#Antibodies #Antibody drug conjugate (ADC) #Biotech #Drug development #Seed funding

Financing ensures development of Adcendo’s ADC asset 

Adcendo, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, has completed a successful Series A extension financing round, raising a further €31 million, following the €51 million Series A financing in April 2021. Read More

#News

#Biotechnology #Drug development #Neurodegenerative disorders #Neuroscience #Seed funding

€28M for neurodegenerative disease treatments

Teitur Trophics, a biotech company developing new treatments for patients suffering from neurodegenerative diseases, has complete a €28M Series A financing.   The financing was co-led by Sunstone Life Science Ventures and Sound Bioventures, with participation from new investors, Industrifonden, Innovestor’s Life Science Fund and P53 Invest. The proceeds will enable… Read More

#Business & Investment #News

Senior couple jogging
#Age-related diseases (ARDs) #Five Alarm Bio #Investment #Seed funding #Start-ups

Anti-ageing therapeutics company completes seed funding

Five Alarm Bio (FAB) has completed a seed investment round, raising over £500K ($605K). The funding will drive proprietary research into novel compounds that extend healthy lifespan of cells and tissues, with therapeutic potential across a broad range of age-related diseases. Investors include Cambridge Angels, Meltwind, o2h Ventures, and SyndicateRoom,… Read More

#News #Start-up Zone

UK financial markets
#BioIndustry Association #Biologics / Biotechnology #Clarivate #Investment #Market reporting #Mergers and acquisitions #Private investment #Seed funding #UK

UK biotech investment drops after bumper years

Investment in UK biotech has fallen from £4.5 billion in 2021 to just £1.8 billion in 2022, mirroring the global economic downturn impacting all sectors.  However, venture capital investment in the sector was the third-best year recorded for the UK, with £1.2 billion raised, new analysis from the UK BioIndustry… Read More

#Business & Investment #News

Gene therapy
#Cell and gene therapy #Gene therapy #Investment #Muscular dystrophy #Seed funding #Start-ups

$5 million raised towards gene therapies for muscular diseases

Myosana Therapeutics has completed a seed funding round totalling over $5 million led by investor John Ballantyne.  The capital will go towards developing Myosana’s gene therapy platform for neuromuscular and cardiac disease, with the goal of identifying the first development candidate for Duchenne muscular dystrophy by 2025.  “Built on decades… Read More

#Business & Investment #News #Start-up Zone